iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?
Brendan Coffey, The Motley Fool
Sat, August 8, 2026 at 9:52 PM GMT+5:30
5 min read
- XBI
+1.86% - ^GSPC
+0.62% - STT
-0.13%
Investors choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) must weigh the high-growth potential of specialized U.S. biotech against a more stable, dividend-paying global healthcare portfolio
Healthcare investors often choose between the stability of established global giants and the high-growth potential of emerging biotechnology. This comparison examines how the broad, international reach of the iShares fund differs from the concentrated, equal-weighted U.S. focus found in the State Street portfolio
Snapshot (cost & size)
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the close of trading on August 6
The State Street SPDR S&P Biotech ETF is slightly more affordable with a 0.35% expense ratio. However, the iShares Global Healthcare ETF offers a significantly higher payout, with a yield gap of 1.05 percentage points over its peer
Performance & risk comparison
What’s inside
The iShares Global Healthcare ETF holds 110 positions, providing exposure to global equities within the pharmaceutical, biotechnology, and medical device industries. Its largest positions include Eli Lilly and Co (NYSE:LLY) at 10.3%, Johnson & Johnson (NYSE:JNJ) at 7%, and Abbvie Inc (NYSE:ABBV) at 5%. The fund is designed for investors seeking broad sector coverage with less volatility than niche sub-sectors. It was launched in 2001. iShares Global Healthcare ETF has paid $1.44 per share over the trailing 12 months, which on its recent ~$101.3 share price works out to a 1.4% yield.
The State Street SPDR S&P Biotech ETF tracks the S&P Biotechnology Select Industry Index using a representative sampling technique across 153 holdings. Its top holdings include Apogee Therapeutics Inc (NASDAQ:APGE) at 1.7%, Oruka Therapeutics Inc (NASDAQ:ORKA) at 1.5%, and Dianthus Therapeutics Inc (NASDAQ:DNTH) at 1.4%. Because it uses a modified equal-weighting system, it provides significant exposure to small- and mid-cap growth stocks rather than just industry titans. It was launched in 2006. State Street SPDR S&P Biotech ETF has paid $0.57 per share over the trailing 12 months, which on its recent ~$154.5 share price works out to a 0.4% yield.
